バイオロジクス市場。世界の産業動向、シェア、サイズ、成長、機会、および2021-2026年の予測Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global biologics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 9% during 2021-2026. Keeping in mind the uncertainties of ... もっと見る
サマリーThe global biologics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use industries. These insights are included in the report as a major market contributor.Biologics, also known as biological drugs, are disease-modifying antirheumatic drugs (DMARDs) made from living organisms or consist of components of living organisms. They include a wide variety of products, such as vaccines, blood, blood components, cells, genes, tissues, allergens, and recombinant proteins, derived from humans, animals, birds, insects, plants, and microorganisms. These products control the production of vital proteins, modify human hormones and cells, while producing substances to activate and suppress the immune system. They also change the manner of operation of natural biologic intracellular and cellular actions. In recent years, biologics have gained immense traction as they are essentially utilized to treat various diseases and conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and other autoimmune diseases. Biologics Market Trends: The global biologics market is primarily driven by the rising incidences and diagnosis of chronic diseases that have necessitated the availability of advanced diagnostics and treatment drugs. Biologics are genetically engineered to target a specific part of the immune system that fuels inflammation. Governments of different countries are also taking initiatives to promote the healthcare sector and ensure the availability of biologics with the onset of coronavirus disease (COVID-19). Furthermore, scientists and researchers are extensively investigating species and expression systems to enhance the productivity of biological products. Moreover, various pharmaceutical companies are undertaking research and development (R&D) activities to improve the efficacy of oral products for rheumatoid arthritis and Crohn’s diseases. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global biologics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, source, product, disease and manufacturing. Breakup by Source: Microbial Mammalian Others Breakup by Product: Monoclonal Antibodies Vaccines Recombinant Proteins Antisense, RNAi and Molecular Therapy Others Breakup by Disease: Oncology Immunological Disorders Cardiovascular Disorders Hematological Disorders Others Breakup by Manufacturing: Outsourced In-House Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc. and Sanofi. Key Questions Answered in This Report: How has the global biologics market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global biologics market? What are the key regional markets? What is the breakup of the market based on the source? What is the breakup of the market based on the product? What is the breakup of the market based on the disease? What is the breakup of the market based on the manufacturing? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global biologics market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Biologics Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Source 6.1 Microbial 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Mammalian 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Others 6.3.1 Market Trends 6.3.2 Market Forecast 7 Market Breakup by Product 7.1 Monoclonal Antibodies 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Vaccines 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Recombinant Proteins 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Antisense, RNAi and Molecular Therapy 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Others 7.5.1 Market Trends 7.5.2 Market Forecast 8 Market Breakup by Disease 8.1 Oncology 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Immunological Disorders 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Cardiovascular Disorders 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Hematological Disorders 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Others 8.5.1 Market Trends 8.5.2 Market Forecast 9 Market Breakup by Manufacturing 9.1 Outsourced 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 In-House 9.2.1 Market Trends 9.2.2 Market Forecast 10 Market Breakup by Region 10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia-Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast 11 SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats 12 Value Chain Analysis 13 Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes 14 Price Analysis 15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 AbbVie Inc. 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.1.4 SWOT Analysis 15.3.2 Amgen Inc. 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.2.3 Financials 15.3.2.4 SWOT Analysis 15.3.3 AstraZeneca plc 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.3.3 Financials 15.3.3.4 SWOT Analysis 15.3.4 F. Hoffmann-La Roche Ltd 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 SWOT Analysis 15.3.5 GlaxoSmithKline plc 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.5.3 Financials 15.3.5.4 SWOT Analysis 15.3.6 Johnson & Johnson 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.6.3 Financials 15.3.6.4 SWOT Analysis 15.3.7 Merck KGaA 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.7.3 Financials 15.3.7.4 SWOT Analysis 15.3.8 Novartis AG 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.8.3 Financials 15.3.8.4 SWOT Analysis 15.3.9 Pfizer Inc. 15.3.9.1 Company Overview 15.3.9.2 Product Portfolio 15.3.9.3 Financials 15.3.9.4 SWOT Analysis 15.3.10 Sanofi 15.3.10.1 Company Overview 15.3.10.2 Product Portfolio 15.3.10.3 Financials 15.3.10.4 SWOT Analysis
SummaryThe global biologics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use industries. These insights are included in the report as a major market contributor.Biologics, also known as biological drugs, are disease-modifying antirheumatic drugs (DMARDs) made from living organisms or consist of components of living organisms. They include a wide variety of products, such as vaccines, blood, blood components, cells, genes, tissues, allergens, and recombinant proteins, derived from humans, animals, birds, insects, plants, and microorganisms. These products control the production of vital proteins, modify human hormones and cells, while producing substances to activate and suppress the immune system. They also change the manner of operation of natural biologic intracellular and cellular actions. In recent years, biologics have gained immense traction as they are essentially utilized to treat various diseases and conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and other autoimmune diseases. Biologics Market Trends: The global biologics market is primarily driven by the rising incidences and diagnosis of chronic diseases that have necessitated the availability of advanced diagnostics and treatment drugs. Biologics are genetically engineered to target a specific part of the immune system that fuels inflammation. Governments of different countries are also taking initiatives to promote the healthcare sector and ensure the availability of biologics with the onset of coronavirus disease (COVID-19). Furthermore, scientists and researchers are extensively investigating species and expression systems to enhance the productivity of biological products. Moreover, various pharmaceutical companies are undertaking research and development (R&D) activities to improve the efficacy of oral products for rheumatoid arthritis and Crohn’s diseases. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global biologics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, source, product, disease and manufacturing. Breakup by Source: Microbial Mammalian Others Breakup by Product: Monoclonal Antibodies Vaccines Recombinant Proteins Antisense, RNAi and Molecular Therapy Others Breakup by Disease: Oncology Immunological Disorders Cardiovascular Disorders Hematological Disorders Others Breakup by Manufacturing: Outsourced In-House Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc. and Sanofi. Key Questions Answered in This Report: How has the global biologics market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global biologics market? What are the key regional markets? What is the breakup of the market based on the source? What is the breakup of the market based on the product? What is the breakup of the market based on the disease? What is the breakup of the market based on the manufacturing? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global biologics market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Biologics Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Source 6.1 Microbial 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Mammalian 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Others 6.3.1 Market Trends 6.3.2 Market Forecast 7 Market Breakup by Product 7.1 Monoclonal Antibodies 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Vaccines 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Recombinant Proteins 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Antisense, RNAi and Molecular Therapy 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Others 7.5.1 Market Trends 7.5.2 Market Forecast 8 Market Breakup by Disease 8.1 Oncology 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Immunological Disorders 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Cardiovascular Disorders 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Hematological Disorders 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Others 8.5.1 Market Trends 8.5.2 Market Forecast 9 Market Breakup by Manufacturing 9.1 Outsourced 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 In-House 9.2.1 Market Trends 9.2.2 Market Forecast 10 Market Breakup by Region 10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia-Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast 11 SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats 12 Value Chain Analysis 13 Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes 14 Price Analysis 15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 AbbVie Inc. 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.1.4 SWOT Analysis 15.3.2 Amgen Inc. 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.2.3 Financials 15.3.2.4 SWOT Analysis 15.3.3 AstraZeneca plc 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.3.3 Financials 15.3.3.4 SWOT Analysis 15.3.4 F. Hoffmann-La Roche Ltd 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 SWOT Analysis 15.3.5 GlaxoSmithKline plc 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.5.3 Financials 15.3.5.4 SWOT Analysis 15.3.6 Johnson & Johnson 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.6.3 Financials 15.3.6.4 SWOT Analysis 15.3.7 Merck KGaA 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.7.3 Financials 15.3.7.4 SWOT Analysis 15.3.8 Novartis AG 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.8.3 Financials 15.3.8.4 SWOT Analysis 15.3.9 Pfizer Inc. 15.3.9.1 Company Overview 15.3.9.2 Product Portfolio 15.3.9.3 Financials 15.3.9.4 SWOT Analysis 15.3.10 Sanofi 15.3.10.1 Company Overview 15.3.10.2 Product Portfolio 15.3.10.3 Financials 15.3.10.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(生物学的製剤)の最新刊レポート
IMARC Services Private Limited.社の生物学的製剤分野での最新刊レポート本レポートと同じKEY WORD(biologics)の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |